Overview

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

FORUM Pharmaceuticals Inc

Collaborators:

INC Research
NeuroCog Trials, Inc.
Syneos Health

Treatments:

Antipsychotic Agents
Nicotinic Agonists